TScan Therapeutics (TCRX) Capital Expenditures Growth (1y) (2021 - 2026)
TScan Therapeutics (TCRX) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -95.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.43% |
| Dec 31, 2025 | -105.07% |
| Sep 30, 2025 | -163.94% |
| Jun 30, 2025 | -170.07% |
| Mar 31, 2025 | 117.30% |
| Dec 31, 2024 | 2,214.29% |
| Sep 30, 2024 | 435.16% |
| Jun 30, 2024 | 1,268.25% |
| Mar 31, 2024 | 2,837.50% |
| Dec 31, 2023 | 67.19% |
| Sep 30, 2023 | 113.82% |
| Jun 30, 2023 | -96.67% |
| Mar 31, 2023 | -95.48% |
| Dec 31, 2022 | -105.79% |
| Sep 30, 2022 | -125.19% |
| Jun 30, 2022 | 229.84% |
| Mar 31, 2022 | -71.09% |
| Dec 31, 2021 | 59.64% |
| Sep 30, 2021 | 447.36% |